Navigation Links
Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products
Date:4/5/2013

CARY, N.C., April 5, 2013 /PRNewswire/ -- Covis Pharmaceuticals, Inc. announced an agreement today to distribute Nilandron® (nilutamide), Plaquenil® (hydroxychloroquine), Rilutek® (riluzole), Uroxatral® (alfuzosin hydrochloride) and Kayexalate® (sodium polystyrene sulfate) in the United States.

The products cover a broad array of treatments and disease states:  Nilandron is used to treat prostate cancer; Plaquenil is an anti-malarial drug; Rilutek treats amyotrophic lateral sclerosis; Uroxatral is used to treat Benign Prostatic Hyperplasia (BPH); and, Kayexalate is prescribed to remove dangerously high levels of potassium in the blood.  With the addition of these products, Covis Pharmaceuticals, Inc. will be distributing 11 brands in the United States.  As part of their mission to ensure availability and access to all products, Covis will continue to offer a patient assistance program

"This agreement underscores our commitment to provide patients with a continuous supply of safe and efficacious therapeutic solutions," said Bill Collins , Chief-Executive-Officer of Covis.  "These additional products will allow Covis to broaden our portfolio with consistent, top quality branded pharmaceuticals."  

The company's current product portfolio includes Lanoxin® (digoxin) Tablets, Lanoxin® (digoxin) IV, Parnate® (tranylcypromine sulfate tablets), Zantac® (ranitidine hydrochloride) Injection, Fortaz® (ceftazidime for injection) and Zinacef® (cefuroxime for injection).  For full prescribing information on these Covis products, including boxed warnings for Parnate®, please visit www.covispharma.com or contact the Company at 919-535-3049.  For full prescribing information on Nilandron Tablets, Plaquenil Tablets, Rilutek Tablets, Uroxatral Tablets, and Kayexalate Powder, including boxed warnings for Nilandron and Plaquenil, please visit http://dailymed.nlm.nih.gov.

Fortaz®, Zinacef®, Lanoxin®, and Parnate® are registered trademarks of the GlaxoSmithKline group of companies. Zantac® is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc., used under license.

About Covis Pharmaceuticals, Inc.   
Covis Pharmaceuticals is a specialty pharmaceutical distributor dedicated to improving the lives of people with life-threatening conditions and chronic illnesses. It is our mission to provide our customers with a continuous supply of safe and efficacious therapeutic solutions. The Website is: www.covispharma.com.


'/>"/>
SOURCE Covis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
2. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
5. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
6. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
7. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
8. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
9. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
10. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
11. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... New Jersey , May 4, 2016 ... its successful completion of an alternative public offering (APO). ... wholly owned operating company, Valeritas, Inc. and a private ... common stock at $5.00 per share. Under ... on May 3, 2016, Valeritas Holdings, Inc. will trade ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Actinic Keratosis Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Actinic Keratosis market valuations and forecast, ...
(Date:5/3/2016)... 2016 Research and Markets has ... Cell Therapy Market Outlook 2020" report to their ... , ,Recombinant technology has improved significantly in past years ... developed in coming years. Many cancer drugs have been ... therapies are also expected to be developed with its ...
Breaking Medicine Technology:
(Date:5/4/2016)... Hills, CA (PRWEB) , ... May 04, 2016 , ... ... care that ex-supermodel Janice Dickinson needed following breast cancer surgery. In March 2016, the ... situ, a type of breast cancer that occurs in the milk ducts, according to ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... medical coding, billing and compliance. In upcoming months, AudioEducator has lined up some ... Every conference is designed to give complete compliance know-how and practical, easy-to-apply advice. ...
(Date:5/4/2016)... ... May 03, 2016 – (PRWEB) May ... and child products, today revealed the non-toxic benefits of its Tutti ... deal with teething pain is just part of the story. These ... are BPA-, PVC-, and phthalate-free. , “Many baby toys contain ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... they acquired Pocono Sterilizer, an equipment sterilization service and sales company located in ... provides medical and research-related equipment and asset management services to the medical and ...
(Date:5/4/2016)... Clara, California (PRWEB) , ... May 04, 2016 ... ... organized by United Scientific Group is scheduled on July 25-27, 2016 at Las ... and other health care professionals from educational institutes and research organizations across the ...
Breaking Medicine News(10 mins):